We are live on ! Find out more
CLVS

Clovis Oncology, Inc.
CLVS

Delisted

CLVS was delisted on the 20th of December, 2022.

Back to rankings

15 hedge funds and large institutions have $525K invested in Clovis Oncology, Inc. in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 90 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

85% less funds holding

Funds holding: 103 → 15 (-88)

98% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 90

99% less capital invested

Capital invested by funds: $42.9M → $525K (-$42.4M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
15
Holders Change
-88
Holders Change %
-85.44%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
90
Calls
$22K
Puts
–
Net Calls
+$22K
Net Calls Change
-$2.59M

Top Buyers

Rank Fund Capital Flow
1
STB
S&T Bank
Pennsylvania
+$13.2K
2
IA
IFP Advisors
Florida
+$33

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$12.1M
2
PAI
Palo Alto Investors
California
-$5.32M
3
BlackRock
BlackRock
New York
-$4.8M
4
QF
QVT Financial
New York
-$4.2M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
SOW
76
State of Wyoming
Wyoming
– -$15K -12,984 Closed
Man Group
77
Man Group
United Kingdom
– -$15K -12,535 Closed
ProShare Advisors
78
ProShare Advisors
Maryland
– -$14K -12,153 Closed
WWM
79
Western Wealth Management
Colorado
– -$13K -10,968 Closed
Bank of America
80
Bank of America
North Carolina
– -$13K -10,958 Closed
JP Morgan Chase
81
JP Morgan Chase
New York
– -$12K -10,183 Closed
TRCT
82
Tower Research Capital (TRC)
New York
– -$6.59K -10,029 -94%
RPCA
83
Running Point Capital Advisors
California
– -$12K -10,000 Closed
SFG
84
SNS Financial Group
Minnesota
– -$12K -10,000 Closed
ACM
85
Antonetti Capital Management
Florida
– -$9K -7,500 Closed
Rockefeller Capital Management
86
Rockefeller Capital Management
New York
– -$3.95K -6,000 -94%
UBS Group
87
UBS Group
Switzerland
– -$5K -4,239 Closed
Fidelity Investments
88
Fidelity Investments
Massachusetts
– -$5K -3,742 Closed
Toronto Dominion Bank
89
Toronto Dominion Bank
Ontario, Canada
– -$3K -2,307 Closed
CAM
90
Close Asset Management
United Kingdom
– -$2K -2,000 Closed
Citigroup
91
Citigroup
New York
– -$2K -1,752 Closed
VNA
92
Valley National Advisers
Pennsylvania
– -$2K -1,505 Closed
CUAMC
93
China Universal Asset Management Company
China
– -$2K -1,353 Closed
BNP Paribas Financial Markets
94
BNP Paribas Financial Markets
France
– -$1.33K -1,117 Closed
Legal & General Group
95
Legal & General Group
United Kingdom
– -$1K -559 Closed
LJHT
96
Laurie J. Hall Trustee
– -$1K -510 Closed
ME
97
McIlrath & Eck
Washington
– -$1K -500 Closed
1 2 3
4

CLVS Hedge Fund Activity: Q4 2022 in Review

15 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2022, worth a combined $525K — down 99% from $42.9M a quarter earlier.

Sellers outnumbered buyers: 90 funds closed out of CLVS and 2 opened new positions — a net loss of 88 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was S&T Bank, adding an estimated $13.2K. The largest seller was Vanguard Group, exiting entirely with an estimated $12.1M sold.

  • 15 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2022, down from 103 in Q3 2022.
  • Funds reported $525K of Clovis Oncology, Inc. stock for Q4 2022, down 99% quarter-over-quarter.
  • 2 funds opened new Clovis Oncology, Inc. positions in Q4 2022 and 90 closed out, a net change of -88 holders.
  • The largest Clovis Oncology, Inc. buyer in Q4 2022 was S&T Bank, an estimated $13.2K added.
  • The largest Clovis Oncology, Inc. seller in Q4 2022 was Vanguard Group, an estimated $12.1M sold.

Based on aggregated 13F filings for Q4 2022.